| NCT06954493 | Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp | COMPLETED | PHASE1 | 2023-07-12 | 2023-11-01 | 2023-11-01 |
| NCT05668429 | ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects | COMPLETED | PHASE1 | 2022-12-14 | 2023-01-28 | 2023-01-28 |
| NCT05178862 | A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole | RECRUITING | PHASE3 | 2022-08-03 | 2027-02-28 | 2026-12-31 |
| NCT05399641 | Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis | COMPLETED | PHASE3 | 2022-05-01 | 2023-08-02 | 2023-05-16 |
| NCT04307082 | ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects | COMPLETED | PHASE1 | 2019-12-05 | 2020-06-30 | 2020-05-29 |
| NCT04092751 | Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects | COMPLETED | PHASE1 | 2019-11-22 | 2019-12-20 | 2019-12-20 |
| NCT04029116 | Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) | COMPLETED | PHASE3 | 2019-10-21 | 2021-11-29 | 2021-09-01 |
| NCT04092725 | Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects | COMPLETED | PHASE1 | 2019-09-09 | 2020-01-03 | 2020-01-03 |
| NCT03987620 | Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis | COMPLETED | PHASE3 | 2019-06-07 | 2020-04-29 | 2020-03-29 |
| NCT03672292 | Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis | TERMINATED | PHASE2 | 2019-01-22 | 2023-03-27 | 2023-03-27 |
| NCT03734991 | Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303) | COMPLETED | PHASE3 | 2019-01-04 | 2019-09-04 | 2019-08-21 |
| NCT03363841 | Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) | COMPLETED | PHASE3 | 2017-11-15 | 2023-05-24 | 2023-04-14 |
| NCT03253094 | Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis | COMPLETED | PHASE2 | 2017-08-01 | 2018-05-04 | 2018-05-04 |
| NCT03059992 | Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment | COMPLETED | PHASE3 | 2017-04-01 | 2023-08-25 | 2023-08-25 |
| NCT02679456 | Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis | COMPLETED | PHASE2 | 2015-11 | 2016-08-05 | 2016-08-05 |
| NCT02244606 | Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis | COMPLETED | PHASE2 | 2014-09 | 2016-08 | 2016-06 |
| NCT01265511 | Study of SCY-635, Pegasys and Copegus in Hepatitis C | COMPLETED | PHASE2 | 2010-11 | 2011-10 | 2011-10 |
| NCT01290965 | Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients | COMPLETED | PHASE1 | 2007-04 | 2009-01 | 2008-12 |